For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
The LANCE® Ultra Human ApoA1 Detection Kit is designed for detection and quantitation of human apolipoprotein A1 (ApoA1) in buffered solution and cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.
Apolipoprotein A1 (ApoA1) is a 45.4 kDa protein that is major protein component of High Density Lipoproteins. One of the primary functions of ApoA1 is the role is plays in promoting fat and cholesterol efflux from tissues for excretion. ApoA1 is currently used a biomarker to predict cardiovascular diseases where levels have been associated with an increased risk of myocardial infarction. This AlphaLISA detection kit allows for the detection of ApoA1 levels in serum, plasma, and cell culture supernatants.
Assay Target | ApoA1 |
---|---|
Assay Target Class | Protein |
Automation Compatible | Yes |
Detection Method | Time-Resolved Fluorescence (TRF), TR-FRET |
Experimental Type | In vitro |
Product Brand Name | LANCE Ultra |
Shipping Condition | Blue Ice |
Therapeutic Area | Metabolic |
Unit Size | 10,000 Assay Points |
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.
This manual explains how to run a LANCE Ultra TR-FRET detection assay for human ApoA1